Have a feature idea you'd love to see implemented?
Let us know!
JAGX Jaguar Health Inc
Price (delayed)
$0.8958
Market cap
$10.57M
P/E Ratio
0.05
Dividend/share
N/A
EPS
$16.51
Enterprise value
$31.57M
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating
Highlights
The EPS has soared by 109% YoY
JAGX's debt is down by 3.6% year-on-year
JAGX's quick ratio has surged by 78% year-on-year but it is down by 20% since the previous quarter
The net income has decreased by 6% QoQ but it has increased by 5% YoY
The equity fell by 19% QoQ
JAGX's gross margin is down by 3.3% year-on-year
Key stats
What are the main financial stats of JAGX
Market
Valuations
Earnings
Shares outstanding
11.8M
Market cap
$10.57M
Enterprise value
$31.57M
Price to earnings (P/E)
0.05
Price to book (P/B)
0.61
Price to sales (P/S)
0.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.01
Revenue
$10.48M
Gross profit
$8.4M
Net income
-$37.74M
EBIT
-$37.15M
EBITDA
-$34.8M
Free cash flow
-$29.01M
Per share
Balance sheet
Liquidity
EPS
$16.51
EPS diluted
$16.51
Free cash flow per share
-$3.1
Book value per share
$1.47
Revenue per share
$1.12
TBVPS
$4.22
Total assets
$58.47M
Total liabilities
$42.88M
Debt
$34.27M
Equity
$13.61M
Working capital
$16.77M
Debt to equity
2.52
Current ratio
1.84
Quick ratio
0.73
Net debt/EBITDA
-0.6
Margins
Efficiency
Dividend
EBITDA margin
-332%
Gross margin
80.1%
Net margin
-360.1%
Operating margin
-287.9%
Return on assets
-66.8%
Return on equity
-318%
Return on invested capital
-88.1%
Return on capital employed
-96.3%
Return on sales
-354.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JAGX stock price
How has the Jaguar Health stock price performed over time
Intraday
-3.28%
1 week
-24.08%
1 month
-7.58%
1 year
-85.5%
YTD
-11.31%
QTD
-11.31%
Financial performance
How have Jaguar Health's revenue and profit performed over time
Revenue
$10.48M
Gross profit
$8.4M
Operating income
-$30.18M
Net income
-$37.74M
Gross margin
80.1%
Net margin
-360.1%
The company's operating income rose by 7% YoY and by 4.8% QoQ
JAGX's operating margin is up by 7% from the previous quarter and by 5% YoY
The net income has decreased by 6% QoQ but it has increased by 5% YoY
Jaguar Health's gross profit has decreased by 5% YoY but it has increased by 3.3% QoQ
Growth
What is Jaguar Health's growth rate over time
Valuation
What is Jaguar Health stock price valuation
P/E
0.05
P/B
0.61
P/S
0.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.01
The EPS has soared by 109% YoY
The price to book (P/B) is 87% lower than the 5-year quarterly average of 4.7 and 39% lower than the last 4 quarters average of 1.0
The equity fell by 19% QoQ
The price to sales (P/S) is 86% lower than the 5-year quarterly average of 5.9 and 20% lower than the last 4 quarters average of 1.0
The company's revenue rose by 2.9% QoQ but it fell by 2.2% YoY
Efficiency
How efficient is Jaguar Health business performance
The ROE has soared by 73% YoY and by 21% QoQ
The ROS fell by 23% YoY and by 4.9% QoQ
The return on invested capital has increased by 17% year-on-year but it has declined by 10% since the previous quarter
The company's return on assets rose by 15% YoY
Dividends
What is JAGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JAGX.
Financial health
How did Jaguar Health financials performed over time
JAGX's total assets is 36% greater than its total liabilities
JAGX's quick ratio has surged by 78% year-on-year but it is down by 20% since the previous quarter
JAGX's total assets is up by 29% year-on-year but it is down by 4.9% since the previous quarter
JAGX's debt is 152% greater than its equity
The debt to equity has plunged by 90% YoY but it has grown by 25% from the previous quarter
The equity fell by 19% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.